0000-0002-0757-3106 Employment
-
Emory University Professor, Director of Medical Oncology2007 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (54)
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer Save
- Supplementary Data 1 from Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer Save
- Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms Save
- “Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality Save
- Data from Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer Save
- Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer Save
- Reply to “From treatment escalation to ultra de‐intensification: When androgen‐deprivation therapy alone remains a rational choice in metastatic hormone‐sensitive prostate cancer” Save
- Neoadjuvant Osimertinib: A Step Ahead or Just a Step? Save
- Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells Save
- A Response to the Letter to the Editor: “Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC” Save